GLTO Quote, Financials, Valuation and Earnings

Cogent Biosciences, Inc. has a net margin of -- compared to Galecto, Inc.'s net margin of --. Galecto, Inc.'s return on equity of -123.72% beat Cogent Biosciences, Inc.'s return on equity of -117.99%.

Galecto, Inc. has a consensus price target of $36.00, signalling upside risk potential of 32.5%. On the other hand Cogent Biosciences, Inc. has an analysts' consensus of $49.09 which suggests that it could grow by 24.12%. Given that Galecto, Inc. has higher upside potential than Cogent Biosciences, Inc., analysts believe Galecto, Inc. is more attractive than Cogent Biosciences, Inc..

Galecto, Inc. has a beta of 1.399, which suggesting that the stock is 39.871% more volatile than S&P 500. In comparison Cogent Biosciences, Inc. has a beta of 0.505, suggesting its less volatile than the S&P 500 by 49.519%.

Galecto, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cogent Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galecto, Inc. pays -- of its earnings as a dividend. Cogent Biosciences, Inc. pays out -- of its earnings as a dividend.

Galecto, Inc. quarterly revenues are --, which are smaller than Cogent Biosciences, Inc. quarterly revenues of --. Galecto, Inc.'s net income of -$3.1M is higher than Cogent Biosciences, Inc.'s net income of -$80.9M. Notably, Galecto, Inc.'s price-to-earnings ratio is -- while Cogent Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galecto, Inc. is -- versus 55.99x for Cogent Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ionis Pharmaceuticals, Inc. has a net margin of -- compared to Galecto, Inc.'s net margin of -82.06%. Galecto, Inc.'s return on equity of -123.72% beat Ionis Pharmaceuticals, Inc.'s return on equity of -43.01%.

Galecto, Inc. has a consensus price target of $36.00, signalling upside risk potential of 32.5%. On the other hand Ionis Pharmaceuticals, Inc. has an analysts' consensus of $87.99 which suggests that it could grow by 10.58%. Given that Galecto, Inc. has higher upside potential than Ionis Pharmaceuticals, Inc., analysts believe Galecto, Inc. is more attractive than Ionis Pharmaceuticals, Inc..

Galecto, Inc. has a beta of 1.399, which suggesting that the stock is 39.871% more volatile than S&P 500. In comparison Ionis Pharmaceuticals, Inc. has a beta of 0.296, suggesting its less volatile than the S&P 500 by 70.45%.

Galecto, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galecto, Inc. pays -- of its earnings as a dividend. Ionis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Galecto, Inc. quarterly revenues are --, which are smaller than Ionis Pharmaceuticals, Inc. quarterly revenues of $156.7M. Galecto, Inc.'s net income of -$3.1M is higher than Ionis Pharmaceuticals, Inc.'s net income of -$128.6M. Notably, Galecto, Inc.'s price-to-earnings ratio is -- while Ionis Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galecto, Inc. is -- versus 13.55x for Ionis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Lyell Immunopharma, Inc. has a net margin of -- compared to Galecto, Inc.'s net margin of -258973.33%. Galecto, Inc.'s return on equity of -123.72% beat Lyell Immunopharma, Inc.'s return on equity of -86.7%.

Galecto, Inc. has a consensus price target of $36.00, signalling upside risk potential of 32.5%. On the other hand Lyell Immunopharma, Inc. has an analysts' consensus of $29.67 which suggests that it could fall by -10.99%. Given that Galecto, Inc. has higher upside potential than Lyell Immunopharma, Inc., analysts believe Galecto, Inc. is more attractive than Lyell Immunopharma, Inc..

Galecto, Inc. has a beta of 1.399, which suggesting that the stock is 39.871% more volatile than S&P 500. In comparison Lyell Immunopharma, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Galecto, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lyell Immunopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galecto, Inc. pays -- of its earnings as a dividend. Lyell Immunopharma, Inc. pays out -- of its earnings as a dividend.

Galecto, Inc. quarterly revenues are --, which are smaller than Lyell Immunopharma, Inc. quarterly revenues of $15K. Galecto, Inc.'s net income of -$3.1M is higher than Lyell Immunopharma, Inc.'s net income of -$38.8M. Notably, Galecto, Inc.'s price-to-earnings ratio is -- while Lyell Immunopharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galecto, Inc. is -- versus 120,861.41x for Lyell Immunopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ovid Therapeutics, Inc. has a net margin of -- compared to Galecto, Inc.'s net margin of -9210.61%. Galecto, Inc.'s return on equity of -123.72% beat Ovid Therapeutics, Inc.'s return on equity of -59.7%.

Galecto, Inc. has a consensus price target of $36.00, signalling upside risk potential of 32.5%. On the other hand Ovid Therapeutics, Inc. has an analysts' consensus of $4.05 which suggests that it could grow by 175.81%. Given that Ovid Therapeutics, Inc. has higher upside potential than Galecto, Inc., analysts believe Ovid Therapeutics, Inc. is more attractive than Galecto, Inc..

Galecto, Inc. has a beta of 1.399, which suggesting that the stock is 39.871% more volatile than S&P 500. In comparison Ovid Therapeutics, Inc. has a beta of 0.045, suggesting its less volatile than the S&P 500 by 95.453%.

Galecto, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ovid Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galecto, Inc. pays -- of its earnings as a dividend. Ovid Therapeutics, Inc. pays out -- of its earnings as a dividend.

Galecto, Inc. quarterly revenues are --, which are smaller than Ovid Therapeutics, Inc. quarterly revenues of $132K. Galecto, Inc.'s net income of -$3.1M is higher than Ovid Therapeutics, Inc.'s net income of -$12.2M. Notably, Galecto, Inc.'s price-to-earnings ratio is -- while Ovid Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galecto, Inc. is -- versus 15.81x for Ovid Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.